Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 49

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 49
---
 MIRA Board unanimously (i) determined that the Merger is fair to, advisable and in the best interests of MIRA and its stockholders, and (ii) approved and declared advisable the Merger Agreement, including the issuance of shares of MIRA Common Stock to the stockholders of SKNY.

| 24 |

The MIRA Board considered the following reasons in reaching its conclusion to approve the Merger Agreement and the Merger:

| ● | the                                                                                    
 Board’s belief, after discussions with MIRA’s senior management and legal counsel,     
 that the Merger is more favorable to MIRA’s stockholders than the potential value that 
 might have resulted from other strategic options available to MIRA;                    |

| ● | the                                                                                             
 Board’s belief, based in part on scientific, regulatory and commercial diligence and            
 an analysis process conducted over several weeks by MIRA’s management and reviewed              
 with the MIRA Board, that SKNY-1 has the potential to become a commercial asset with a sizable  
 potential market and efficient commercialization plan and may create value for the stockholders 
 of MIRA and an opportunity for MIRA’s stockholders to participate in the resulting              
 potential growth for MIRA;                                                                      |

| ● | based                                                                                          
 on review with the management of MIRA, the ability to expand MIRA’s product offering           
 and engage a new product market, and the likelihood that the post-Merger company would possess 
 sufficient financial resources to allow the management team to focus on such plans;            |

| ● | the                                                                                       
 possibility that the post-Merger company would be able to take advantage of the potential 
 benefits resulting from the combination of MIRA’s public company structure with SKNYs     
 drug candidates to raise additional funds in the future;                                  |

| ● | the                                                                                        
 strength of the balance sheet of the post-Merger company, which includes the $5 million of 
 cash or cash equivalents contributed as part of the Merger transaction;                    |

| ● | MIRA                                                                                          
 Board’s belief, based in part on scientific, regulatory and commercial diligence and          
 an analysis process conducted over several weeks by MIRA’s management and reviewed            
 with the MIRA Board, that SKNY-1 has significant market potential and is supported by a clear 
 and efficient development and commercialization roadmap, which may create long-term value     
 for the stockholders of the combined company and provide MIRA’s stockholders with an          
 opportunity to participate in the potential growth of the combined enterprise; and            |

| ●